MetaCap

Aspire-Lakewood (ASBP) vs CalciMedica (CALC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aspire-Lakewood (ASBP) has outperformed CalciMedica (CALC) over the past year, gaining 83.8% versus a loss of 92.3%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $8.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASBP+83.76%CALC-92.34%
+150%+21%-108%
Nov 21, 20251 yearNov 20, 2026
ASBP-98.29%CALC-94.99%
+41%-33%-107%
Jun 12, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASBP versus CALC key metrics
MetricASBPCALC
Share price$7.13$1.26
Market cap$10.00M$8.69M
1-day change-5.44%+7.69%
YTD return+35.04%-96.18%
1-year return+83.76%-92.34%
EPS (TTM)$-30.89$-4.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.20K—
Net income (latest FY)$-24.48M$-29.56M
Gross margin-1.87%—
Operating margin-312016.95%—
Net margin-394725.06%—
52-week high$9.50$36.00
52-week low$0.11$1.00
Distance from 52-week high-24.95%-96.50%
Analyst consensus—none
Avg. price target upside—+3868.25%
Average volume29.24K80.15K
Shares outstanding1.40M6.90M
Employees—15
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ASBP has outperformed CALC by 176.1 percentage points over the past year.

About Aspire-Lakewood

ASBP stock →

Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.

Health Care · Biotechnology: Pharmaceutical Preparations

About CalciMedica

CALC stock →

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ASBP vs CALC FAQ

Which is bigger, Aspire-Lakewood or CalciMedica?

Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $8.69M for CalciMedica (CALC).

Which stock has performed better over the past year, ASBP or CALC?

ASBP returned +83.76% over the past 12 months, compared with -92.34% for CALC (price return, excluding dividends). Past performance does not predict future results.

Are Aspire-Lakewood and CalciMedica in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons